Medical/Pharmaceuticals

Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery

CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced the appointment of Dr.Hongjiang Miao as Chief AI Offic...

2025-12-04 10:01 1488

INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

NANJING, China and GAITHERSBURG, Md., Dec. 3, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation ("CDE") of the National Medical Products Adm...

2025-12-04 09:57 868

High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology

SUZHOU, China, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical...

2025-12-04 08:00 951

POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results

GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases inChina, today announced its unaudited financial results for the six months endedJune 30, 2025. Mr. Zhenyang Shi, Chairma...

2025-12-04 05:15 3302

ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting

Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response and Enable Patient Stratification for Drug Development. PALO ALTO, Calif., Dec. 3, 2025 /PRNewswire/ -- ImpriMed

2025-12-04 01:00 1033

Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®

* FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases * OMLYCLO® (omalizumab-igec) is the first and only ...

2025-12-03 08:43 1218

Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025

Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announced it will present 14 stu...

2025-12-02 22:10 3207

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity ...

2025-12-02 22:00 2150

Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1

* AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end approach to new modality drug discovery. ...

2025-12-02 22:00 1726

L&C Bio's 'Re2O' Emerges as a Leading K-Medical Tour Procedure Within One Year of Launch

– Surging global demand drives rapid adoption across domestic and international medical sectors – SEONGNAM, South Korea, Dec. 2, 2025 /PRNewswire/ -- L&C Bio (KOSDAQ: 290650, Co-CEOsHwan-Chul Lee and Jae-Ho Lee), a leading company in human tissue–based regenerative medicine, announced that its p...

2025-12-02 22:00 755

Yuyu Pharma Announces Strategic Investment in Dalan Animal Health as Part of Accelerated Global Expansion in Animal Health

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Yuyu Pharma announced today that it has completed a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company advancing an innate immunity–based platform for developing vaccines for honeybees and shrimp. The investment marks a...

2025-12-02 22:00 1198

GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper

* Officially recognized by WHO as a standard varicella vaccine strain alongside Oka * Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its propriet...

2025-12-02 13:00 1058

United Imaging Broadens Imaging Portfolio and Advances Native AI at RSNA 2025

The company brings a full array of technology to its two booths in Chicago, showcasing another year of increasing R&D and investment. CHICAGO, Dec. 1, 2025 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will showcase a range ...

2025-12-02 00:00 1003

HZICC:Innovation hub: Hangzhou witness new voices and new ambitions

HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- The remarkable achievements of past winners of Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents have set a powerful example, inspiring a new wave of international innovators to bring their projects toHangzhou. Among this yea...

2025-11-28 21:25 1201

HZICC:Unlocked potential: why global innovators choose Hangzhou

HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- Meng Jintao, winner of the 2024 Hangzhou's Innovation & Entrepreneurship Competition for Overseas Talents, exemplifies this journey. His project on "All-Iron Redox Flow Battery Technology"--dubbed a "giant movable power bank"--has already secured let...

2025-11-28 21:19 1304

BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough

* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma * The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...

2025-11-28 21:00 1170

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

* Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. * The collaboration includes precli...

2025-11-28 13:00 1260

Keep Your Respiratory Health Strong This Season With VARON Black Friday Offers

NEW YORK, Nov. 27, 2025 /PRNewswire/ -- As the holiday season approaches, respiratory health becomes a top priority for individuals living with chronic conditions such as COPD, sleep apnea, or other lung diseases. VARON,

2025-11-28 06:09 1293

Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market

SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") andSouth Korea's FatiAbGen Co., Ltd. today jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the K...

2025-11-27 22:00 1307

SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation

New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in ...

2025-11-27 10:39 1149
1 ... 6789101112 ... 250